Overview

NYU langone Health’s Perlmutter Cancer Center has announced‌ the establishment of a new Gastrointestinal (GI) ‌Cancer Center, co-directed​ by Anirban Maitra, MD, and Manuel‌ Hidalgo, MD. ⁤This‍ initiative aims⁤ to accelerate scientific revelation and translate research ⁣into improved treatments for patients with⁢ GI cancers. The center will integrate ⁢multidisciplinary​ teams ‍of surgical, radiation, and ⁤medical oncologists, gastroenterologists, and researchers.

Leadership and⁤ expertise

Anirban Maitra, MD, ​is recognized globally for ‌his contributions to pancreatic cancer research, notably in early ⁤detection. Manuel Hidalgo, MD, brings⁤ extensive expertise in the development of novel therapies for GI cancers. Both physicians are highly regarded in thier fields and​ will play a crucial role in shaping the center’s strategic direction.

John P. Leonard, MD, chief‍ of the Division of Hematology‍ and ‌Medical Oncology at NYU Grossman⁤ School of Medicine and director of the Center​ for Blood Cancers at Perlmutter Cancer‌ Center, ‍emphasized the center’s commitment to translating scientific breakthroughs into tangible ⁣benefits for ⁤patients.

Focus Areas and Integration

The GI‍ Cancer Center will focus on a range of gastrointestinal cancers, including ⁣but not limited to:

• Pancreatic ⁤Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Hepatobiliary Cancers (liver, gallbladder, bile duct)

A key ​aspect of the center’s approach is​ the integration of multidisciplinary ‍teams.This collaborative model will ensure that patients‍ receive thorough, ⁤coordinated care tailored to their specific needs. The center will leverage the existing strengths ‍of NYU Langone’s surgical, radiation, and ⁤medical oncology departments, and also its ‍gastroenterology and⁤ research ​programs.

Research and Clinical ​Translation

The center’s mission⁤ centers on accelerating the​ translation of research findings into‍ new treatments. This ​will involve:

• Conducting cutting-edge ⁢research to identify novel⁢ therapeutic targets.
• Developing and testing innovative therapies in clinical trials.
• Utilizing advanced technologies,such as genomics⁤ and imaging,to personalize ​treatment strategies.